PEPG Overview

U.S. Stock Futures: U.S. stock futures showed mixed results, with Dow futures down approximately 0.1% on Monday morning.

Meihua International Medical Technologies: Shares of Meihua International Medical Technologies fell 32.9% in pre-market trading after the announcement of its delisting from Nasdaq.

Other Notable Stock Movements: Several other stocks experienced significant declines in pre-market trading, including SMX down 17.2%, Gulf Resources down 16.1%, and Wheeler Real Estate down 16.1%.

Market Reactions: The market saw various stocks decline after previous gains, with Fly-E Group and Ecarx Holdings also reporting notable drops due to regulatory issues and market fluctuations.

Sarepta Therapeutics' Stock Surge: Shares of Sarepta Therapeutics rose 7% following positive updates on its phase I/II study of SRP-1003, a potential treatment for type 1 myotonic dystrophy, including successful patient enrollment and safety committee approval.

Milestone Payments and Partnerships: The announcement triggered a $200 million milestone payment to Arrowhead Pharmaceuticals, part of a multi-billion-dollar licensing deal, with Sarepta having previously made a $100 million payment earlier this year.

Investor Sentiment: Despite the stock's significant decline of nearly 85% year-to-date, investor optimism has increased due to the positive study updates, contrasting with challenges faced by other companies in the same therapeutic area.

Future Developments: Sarepta is currently dosing patients in the fourth cohort of the study and plans to begin the fifth cohort in early 2026, with initial data expected early next year for SRP-1003 and other clinical-stage programs.

Price Target Update: The average one-year price target for PepGen has been revised to $10.20 per share, reflecting a 17.65% increase from the previous estimate of $8.67, with a range from $3.03 to $21.00 per share.

Fund Sentiment: There are 159 funds reporting positions in PepGen, with a 7.43% increase in ownership over the last quarter, and total shares owned by institutions rising by 124.38% to 54,560K shares.

Major Shareholders: Ra Capital Management and Viking Global Investors significantly increased their holdings in PepGen, with Ra Capital raising its ownership by 46.72% and Viking by 57.43% over the last quarter.

Market Outlook: The put/call ratio for PepGen is 0.40, indicating a bullish sentiment among investors, while Fintel provides comprehensive investment research and data for individual investors and small hedge funds.

Market Reaction: Dyne Therapeutics and PepGen saw significant stock increases of approximately 41% and 21%, respectively, following Novartis' $12 billion acquisition of Avidity Biosciences.

Avidity's Developments: Avidity is advancing treatments for rare muscular dystrophies, including Del-zota for Duchenne muscular dystrophy and other candidates for myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy.

Dyne's Pipeline: Dyne Therapeutics is working on two candidates for myotonic dystrophy type 1, utilizing its proprietary FORCE platform, with data expected by mid-2026.

PepGen's Trials: PepGen is developing PGN-EDODM1 for myotonic dystrophy type 1 and is currently recruiting for two clinical trials, one in phase 1 and another in phase 2.